Anondita Medicare Ltd · ANONDITA⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
₹31 Cr
—
₹46 Cr
—
₹54 Cr
—
₹83 Cr
—
20-quarter listed-company comparison
Contraceptives/Protectives Stocks in India
Contraceptives/Protectives: Cupid Ltd owns the largest revenue base AND the fastest current growth.
01 · the index people search for
Nifty Contraceptives/Protectives Index — Constituents & Performance
The Contraceptives/Protectives companies below are the listed Indian Contraceptives/Protectives universe this page tracks — the same constituent set people search for as the Nifty Contraceptives/Protectives index. Every figure is equal-weighted across those companies, so one large constituent cannot set the reading. Each number carries its own as-of date.
02 · sector relative strength, before individual stocks
Is Contraceptives/Protectives outperforming NIFTY 500?
Contraceptives/Protectives has outperformed NIFTY 500 by 429.9% over the last 52 weeks. Over 13 weeks the gap is a lead of 41.6%. 1 of 1 covered company currently beats NIFTY on Mansfield relative strength, so leadership inside the sector is broad. Cupid Ltd is the strongest against the sector itself at +38.7%. Readings are as of 2026-08-09.
+41.6%Sector vs NIFTY 500 · 13 weeks
+429.9%Sector vs NIFTY 500 · 52 weeks
1/1Stocks leading NIFTY 500
1/1Stocks leading sector
Sector metric: 97.7 as of 2026-08-09 · NARROWING · rising.
The central tension: current leadership is concentrated, so durability matters more than rank.
Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.
Bottom line
Contraceptives/Protectives has outperformed NIFTY 500 by 429.9% over 52 weeks and 41.6% over 13 weeks. 1 of 1 covered companies beat NIFTY on Mansfield relative strength, while 1 of 1 beat the sector itself. Cupid Ltd leads with revenue of ₹453 crore, based on 1 of 2 comparable companies through Jun 2026.
Companies
2
complete canonical membership
Combined market value
₹37.1K Cr
Cupid Ltd
Revenue growing
1/1
positive TTM year-on-year growth
Beating NIFTY 500
1/1
positive Mansfield relative strength
Comparing 1 of 2
03 · research priority, made explicit
Best Contraceptives/Protectives Stocks in India (Aug 2026), Ranked by Data
4-Factor Sector Score
An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.
Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%
Cupid Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 90% evidence confidence.
How this score is built, and what the marks mean
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Top 10 Contraceptives/Protectives Stocks in India
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Cupid LtdCUPID | 88.7/100Sector-leading setup90% evidence | LEADER | 35.0/35 Revenue 100% · PAT 100% · OPM change 11 pp 100% evidence | 20.0/25 ROCE 33.5% · OPM 39% 100% evidence | 13.7/20 P/E 257× · PEG 0.96 50% evidence | 20.0/20 RS sector 38.7% · RS bench 156.9% · 1Y 729.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 35 + 20 + 13.7 + 20 = 88.7 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Anondita Medicare LtdANONDITA | 59.2/100Thin evidence · provisional33% evidence | FADING | 17.7/35 Revenue — · PAT — · OPM change 3 pp 26% evidence | 21.5/25 ROCE 43.6% · OPM 38% 95% evidence | 10.0/20 P/E 56.3× · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —10 of 12 weeks ahead 0% evidence |
| Exact sum: 17.7 + 21.5 + 10 + 10 = 59.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
04 · what price has already done
Market action
Cupid Ltd has the strongest one-year price move in Contraceptives/Protectives at +729.6%. It also leads on Mansfield relative strength against NIFTY at +156.9%. 1 of 1 covered company is above zero on that measure. Every line covers 313 weekly closes through 2026-08-07.
Price and relative strength
Every company, the sector's own index and NIFTY 500 all start level on the left edge of the window, so only the distance between the lines counts — the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.
How far ahead of or behind NIFTY 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS NIFTY 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.
The same measure taken against Contraceptives/Protectives itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.
05 · compare level, then change
Revenue Scale & Growth Durability
Cupid Ltd has the highest Revenue among the 2 Contraceptives/Protectives companies compared here, at ₹453 crore. The same company also holds the highest Revenue growth, at the 100% top of the scoring scale. 1 of 2 companies report a comparable reading, the latest through Jun 2026. Its Revenue series carries 20 reported observations across the 20-quarter window.
What the numbers say: Cupid Ltd is the scale leader at ₹453 crore, Cupid Ltd's growth is stored at the ≥100% scoring cap; the uncapped TTM change is 122.1% from a ₹453 crore base, with 20 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.
LeaderCupid Ltd · ₹453 crore
GapNot enough peers
Persistence7/8 recent comparable periods
Coverage1/2 companies · 24 observations
Investor read: Cupid Ltd is the scale benchmark; Cupid Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.
This conclusion weakens if: Cupid Ltd's growth falls below Cupid Ltd's for two consecutive comparable reports while operating margin also compresses.
Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
1Cupid Ltd CUPID₹453 Cr
Revenue growthfastest growers
1Cupid Ltd CUPID100%
Revenue · company comparison
1/2 level · 1/2 change
On every company-comparison chart on this page: solid lines show level, dotted lines show change when “Both” is selected, and a missing report breaks the line rather than being invented.
All-company data · latest reported quarter
In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Revenue | Revenue growth | Reported |
|---|---|---|---|
| Cupid Ltd CUPID | ₹155 Cr | 158% | Jun 2026 |
| Anondita Medicare Ltd ANONDITA⚠ unverified | ₹83 Cr | 80% | Mar 2026 |
Full 20-quarter history · every available company
Revenue · reported quarter history
Cupid Ltd · CUPID
₹34 Cr
₹37 Cr
₹31 Cr
₹31 Cr
₹45 Cr
₹43 Cr
₹42 Cr
₹35 Cr
₹36 Cr
₹40 Cr
₹63 Cr
₹39 Cr
₹42 Cr
₹46 Cr
₹56 Cr
₹60 Cr
₹84 Cr
₹94 Cr
₹120 Cr
₹155 Cr
Revenue growth · reported quarter history
Anondita Medicare Ltd · ANONDITA⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
74%
—
80%
—
Cupid Ltd · CUPID
—
—
-26%
-8.8%
32%
16%
35%
13%
-20%
-7.0%
50%
11%
17%
15%
-11%
54%
100%
104%
114%
158%
06 · compare level, then change
Operating Economics & Margin Trend
Cupid Ltd has the highest OPM among the 2 Contraceptives/Protectives companies compared here, at 39%. Anondita Medicare Ltd is next at 38%. The same company also holds the highest Margin change, at +11 percentage points. 2 of 2 companies report a comparable reading, the latest through Jun 2026. Its OPM series carries 20 reported observations across the 20-quarter window.
What the numbers say: Cupid Ltd leads both opm at 39% and margin change at +11 percentage points.
LeaderCupid Ltd · 39%
Gap2.6% versus #2 · Anondita Medicare Ltd
Persistence6/8 recent comparable periods
Coverage2/2 companies · 24 observations
Investor read: Cupid Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current margin change signal.
Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
OPMhighest
1Cupid Ltd CUPID39%
2Anondita Medicare Ltd ANONDITA⚠ unverified38%
Margin changefastest expanders
1Cupid Ltd CUPID+11.0 pp
2Anondita Medicare Ltd ANONDITA⚠ unverified+3.0 pp
Operating margin · company comparison
2/2 level · 2/2 change
All-company data · latest reported quarter
| Company | OPM | Margin change | Reported |
|---|---|---|---|
| Cupid Ltd CUPID | 39% | +11.0 pp | Jun 2026 |
| Anondita Medicare Ltd ANONDITA⚠ unverified | 38% | +3.0 pp | Mar 2026 |
Full 20-quarter history · every available company
OPM · reported quarter history
Anondita Medicare Ltd · ANONDITA⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
31%
—
35%
—
35%
—
38%
—
Cupid Ltd · CUPID
20%
12%
18%
17%
25%
33%
26%
9.0%
20%
30%
49%
17%
25%
25%
24%
28%
34%
37%
31%
39%
Margin change · reported quarter history
Anondita Medicare Ltd · ANONDITA⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
+4.0 pp
—
+3.0 pp
—
Cupid Ltd · CUPID
−12.8 pp
−15.8 pp
−3.7 pp
−8.3 pp
+5.0 pp
+21.0 pp
+7.7 pp
−7.7 pp
−5.0 pp
−3.0 pp
+23.0 pp
+8.0 pp
+5.0 pp
−5.0 pp
−25.0 pp
+11.0 pp
+9.0 pp
+12.0 pp
+7.0 pp
+11.0 pp
07 · compare level, then change
Profit Scale & Acceleration
Cupid Ltd has the highest Net profit among the 2 Contraceptives/Protectives companies compared here, at ₹137 crore. The same company also holds the highest Profit growth, at the 100% top of the scoring scale. 1 of 2 companies report a comparable reading, the latest through Jun 2026. Its Net profit series carries 20 reported observations across the 20-quarter window.
What the numbers say: Cupid Ltd leads with ₹137 crore of TTM profit, Cupid Ltd shows ≥100% on the scoring scale (185.4% uncapped) growth from a ₹137 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.
LeaderCupid Ltd · ₹137 crore
GapNot enough peers
Persistence7/8 recent comparable periods
Coverage1/2 companies · 24 observations
Investor read: Cupid Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.
Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
1Cupid Ltd CUPID₹137 Cr
Profit growthfastest growers
1Cupid Ltd CUPID100%
Net profit · company comparison
1/2 level · 1/2 change
All-company data · latest reported quarter
| Company | Net profit | Profit growth | Reported |
|---|---|---|---|
| Cupid Ltd CUPID | ₹44 Cr | 193% | Jun 2026 |
| Anondita Medicare Ltd ANONDITA⚠ unverified | ₹21 Cr | 110% | Mar 2026 |
Full 20-quarter history · every available company
Net profit · reported quarter history
Anondita Medicare Ltd · ANONDITA⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
₹6 Cr
—
₹10 Cr
—
₹13 Cr
—
₹21 Cr
—
Cupid Ltd · CUPID
₹4 Cr
₹2 Cr
₹5 Cr
₹5 Cr
₹9 Cr
₹10 Cr
₹8 Cr
₹2 Cr
₹5 Cr
₹9 Cr
₹24 Cr
₹8 Cr
₹10 Cr
₹11 Cr
₹12 Cr
₹15 Cr
₹24 Cr
₹33 Cr
₹36 Cr
₹44 Cr
Profit growth · reported quarter history
Anondita Medicare Ltd · ANONDITA⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
117%
—
110%
—
Cupid Ltd · CUPID
—
—
-17%
-17%
125%
400%
60%
-60%
-44%
-10%
200%
300%
100%
22%
-50%
88%
140%
200%
200%
193%
08 · compare level, then change
Return On Capital Employed
Anondita Medicare Ltd has the highest ROCE among the 2 Contraceptives/Protectives companies compared here, at 43.6%. Cupid Ltd is next at 33.5%. Cupid Ltd has the highest ROCE change at +13 percentage points, so level and change sit with different companies. 2 of 2 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Anondita Medicare Ltd leads ROCE at 43.6%, 10.1 percentage points above Cupid Ltd. Cupid Ltd has the strongest latest improvement at +13 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.
LeaderAnondita Medicare Ltd · 43.6%
Gap30.1% versus #2 · Cupid Ltd
PersistenceNot enough history
Coverage2/2 companies · 18 observations
Investor read: Anondita Medicare Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current roce change signal.
ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCEhighest
1Anondita Medicare Ltd ANONDITA⚠ unverified44%
2Cupid Ltd CUPID34%
ROCE changefastest improvers
1Cupid Ltd CUPID+13.0 pp
2Anondita Medicare Ltd ANONDITA⚠ unverified−18.0 pp
Return on capital · company comparison
2/2 level · 2/2 change
All-company data · latest reported quarter
| Company | ROCE | ROCE change | Reported |
|---|---|---|---|
| Anondita Medicare Ltd ANONDITA⚠ unverified | 32% | — | Mar 2026 |
| Cupid Ltd CUPID | 24% | +13.0 pp | Jun 2026 |
Full 20-quarter history · every available company
ROCE · reported quarter history
Anondita Medicare Ltd · ANONDITA⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
23%
—
32%
—
Cupid Ltd · CUPID
22%
19%
14%
—
16%
—
23%
—
16%
20%
16%
26%
18%
29%
11%
21%
17%
32%
24%
—
ROCE change · reported quarter history
Cupid Ltd · CUPID
—
—
—
—
−6.1 pp
—
+8.5 pp
—
−0.1 pp
—
−6.9 pp
—
+1.5 pp
+9.6 pp
−5.1 pp
−5.8 pp
−1.0 pp
+2.8 pp
+13.0 pp
—
09 · compare level, then change
Valuation Against Growth & Quality
Cupid Ltd has the lowest PEG among the 2 Contraceptives/Protectives companies compared here, at 0.96×. Anondita Medicare Ltd has the lowest P/E at 56.3×, so level and change sit with different companies. 1 of 2 companies report a comparable reading, the latest through Jun 2026.
What the numbers say: Cupid Ltd has the lowest comparable PEG at 0.96×. Only 1 of 2 companies have earnings and growth steady enough for the ratio to mean anything, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.
LeaderCupid Ltd · 0.96×
GapNot enough peers
Persistence0/8 recent comparable periods
Coverage1/2 companies · 2 observations
Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.
This conclusion weakens if: The next two comparable reports reverse the current p/e signal.
PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.
PEGlowest PEG
1Cupid Ltd CUPID1.0
P/Elowest P/E
1Anondita Medicare Ltd ANONDITA⚠ unverified56.3
2Cupid Ltd CUPID257.0
Valuation · company comparison
1/2 level · 2/2 change
All-company data · latest reported quarter
| Company | PEG | P/E | Reported |
|---|---|---|---|
| Cupid Ltd CUPID | 1.0 | 228.2 | Jun 2026 |
| Anondita Medicare Ltd ANONDITA⚠ unverified | — | 55.4 | Mar 2026 |
Full 20-quarter history · every available company
PEG · reported quarter history
Cupid Ltd · CUPID
—
—
—
—
—
—
—
—
—
2.7
—
—
1.0
—
—
—
—
—
—
—
P/E · reported quarter history
Anondita Medicare Ltd · ANONDITA⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
29.8
—
55.4
—
Cupid Ltd · CUPID
10.4
10.1
16.6
15.1
16.7
19.7
18.0
18.0
29.2
80.1
110.5
60.7
55.7
40.7
33.3
71.3
139.1
309.2
136.4
228.2
10 · before the conclusion, check the blind spots
What can make this comparison misleading?
This Contraceptives/Protectives comparison names 6 specific ways its own evidence can mislead, all listed below. All 2 companies here report on comparable dates, so no rank carries a stale marker. 1 draws at least one figure from a second feed with too little overlap to cross-check. 3 of the 5 ranked sections have fewer than three usable current readings.
Keep these limits visible
- A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
- A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
- The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- 1 company draws at least one figure from a second data feed with too little overlapping history to cross-check against the primary source; it is marked unverified wherever that figure appears.
- Thin comparisons: Revenue, Net profit, Valuation have fewer than three usable current readings.
11 · evidence and freshness
How was this comparison built?
This comparison is built from the reported filings of 2 Contraceptives/Protectives companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Jun 2026 and market data through 2026-08-07. A second data feed fills gaps only after identity and scale reconciliation, and missing observations are never interpolated.
FundamentalsThrough Jun 2026 · up to 20 quarters per company
Market dataThrough 2026-08-07 · weekly price and relative-strength history
Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
Source standing1 cross-checked · 1 unverified · 0 withheld, of 2 graded companies.
How a second data feed is admitted, and what happens when it disagrees
A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree the figures fill silently. Where there is too little shared history to compare, the figures are still drawn — they are the only evidence there is — and marked ⚠ unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from.
12 · questions investors ask, short speakable answers
Contraceptives/Protectives company comparison FAQs
These 23 answers restate the Contraceptives/Protectives comparison above in question form. Every one is computed from the same 2 companies and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-08-07. Nothing here is estimated, and none of it is a recommendation.
Is the Contraceptives/Protectives sector outperforming NIFTY 500?
Contraceptives/Protectives has outperformed NIFTY 500 by 429.9% over 52 weeks and 41.6% over 13 weeks. 1 of 1 covered companies beat NIFTY on Mansfield relative strength, while 1 of 1 beat the sector itself.
Which Contraceptives/Protectives company is largest by revenue?
Cupid Ltd leads with revenue of ₹453 crore, based on 1 of 2 comparable companies through Jun 2026.
Which Contraceptives/Protectives company is growing fastest?
Cupid Ltd has the fastest current revenue growth at 100%, across 1 of 2 comparable companies.
Which Contraceptives/Protectives company has the strongest 4-Factor Sector Score?
Cupid Ltd ranks first at 88.7/100 with 90% evidence confidence. The score prioritizes research; it is not a buy recommendation.
Which Contraceptives/Protectives company has the lowest comparable PEG?
Cupid Ltd has the lowest comparable PEG at 0.96, among 1 of 2 companies whose earnings and growth are steady enough for the ratio to mean anything.
How much history does this Contraceptives/Protectives comparison include?
The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.
How is the 4-Factor Sector Score calculated?
The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.
Is there a Nifty Contraceptives/Protectives index?
NSE India maintains Nifty indices for several broad sector categories — Nifty Bank, Nifty IT, Nifty Pharma and others — but not for every sub-sector grouping on this site. Whether or not an official Nifty index covers Contraceptives/Protectives, this page builds its own equal-weight basket of 2 listed Contraceptives/Protectives companies — one company, one vote, regardless of market value — so no single large company dominates the reading. Figures are as of Jun 2026.
Which are the best Contraceptives/Protectives stocks in India?
Ranked by this page's four-factor score, Cupid Ltd places first among 2 listed Contraceptives/Protectives companies, followed by Anondita Medicare Ltd. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Jun 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser.
How many Contraceptives/Protectives stocks are listed in India?
This comparison covers 2 listed Contraceptives/Protectives companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Jun 2026.
Which Contraceptives/Protectives company is the biggest?
Cupid Ltd is the largest, with trailing-twelve-month revenue of ₹453 crore. That covers 1 of 2 companies with comparable reporting through Jun 2026.
Which Contraceptives/Protectives company has the best profit margins?
Cupid Ltd has the highest operating margin at 39%, from 2 of 2 comparable companies. Cupid Ltd shows the biggest recent improvement, at +11 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.
Which Contraceptives/Protectives company makes the most profit?
Cupid Ltd earns the most, at ₹137 crore of trailing-twelve-month net profit, from 1 of 2 comparable companies. Cupid Ltd has the fastest profit growth at the ≥100% scoring cap, though growth off a small or recovering profit base overstates how much has actually changed.
Which Contraceptives/Protectives company earns the highest return on capital?
Anondita Medicare Ltd leads on return on capital employed at 43.6%, across 2 of 2 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.
Which Contraceptives/Protectives stock is the cheapest?
On PEG — where a LOWER number is cheaper — Cupid Ltd screens cheapest at 0.96×. Only 1 of 2 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.
Is the Contraceptives/Protectives sector beating the market?
Contraceptives/Protectives has outperformed NIFTY 500 by 429.9% over the last 52 weeks and 41.6% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 1 of 1 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.
Which Contraceptives/Protectives stock has the strongest price momentum?
Cupid Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.
Which Contraceptives/Protectives company scores highest for research priority?
Cupid Ltd scores 88.7 out of 100 with 90% evidence confidence, from 35 points on growth and earnings, 20 on capital efficiency, 13.7 on valuation and 20 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.
How many Contraceptives/Protectives companies does this comparison cover, and over what period?
It compares 2 listed companies over up to 20 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.
What is the total market cap of the Contraceptives/Protectives sector?
The 2 Contraceptives/Protectives companies on this page carry ₹37,130 crore of combined market value. Cupid Ltd is the largest at ₹35,248 crore, about 95% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-15.
How is the Contraceptives/Protectives sector performing?
1 of the 1 covered Contraceptives/Protectives companies are beating NIFTY 500 on Mansfield relative strength. The sector itself is 429.9% ahead of NIFTY 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-15.
Why are some values on this page blank?
A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.
Is this investment advice?
No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.